Literature DB >> 21275972

Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders?

Ian Hincks, Barrie E Woodcock, Jecko Thachil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21275972     DOI： 10.1111/j.1365-2141.2010.08563.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.

Authors:  Michael Zhong; Anneke van der Walt; Maria Pia Campagna; Jim Stankovich; Helmut Butzkueven; Vilija Jokubaitis
Journal:  Neurotherapeutics       Date:  2020-10-14       Impact factor: 7.620

2.  Late-onset neutropenia following rituximab treatment for rheumatologic conditions.

Authors:  Gabriel S Breuer; Michael Ehrenfeld; Itzhak Rosner; Alexandra Balbir-Gurman; Devy Zisman; Shirley Oren; Daphna Paran
Journal:  Clin Rheumatol       Date:  2014-03-06       Impact factor: 2.980

3.  Rituximab-induced late-onset neutropenia.

Authors:  Kamal Kant Sahu; Nathan Petrou; Zachary Cohn; Shrinkhala Khanna
Journal:  BMJ Case Rep       Date:  2019-12-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.